Blog
Trinity: Deep Dive
The AI Context Layer: The Missing Link in AI-Ready Data
Most commercial life sciences organizations have invested heavily in data. They have lakehouses, harmonized data feeds, and dashboard environments like Power BI, Tableau, and Snowflake that teams rely on daily. These tools already carry semantic models: metric definitions, schema relationships, and governed sources. The analytics infrastructure is real. Yet when they try to build AI on top of it, they hit the same wall: the AI doesn’t understand their business.
Filter posts by:
Blog
AIML-Based Patient Finding—Threading the Needle in the Haystack
For life sciences companies focused on rare diseases, accurate patient finding is a worthy challenge—one deserving dedicated time and resource to tackling and solving. The benefit of enrolling even one new patient is large, both for the lives of patients in...
Blog
The Future of AI for Market Access: An ISPOR US 2023 Recap
This year Trinity team members at ISPOR 2023 attended several symposia and presentations on the use of Artificial Intelligence (AI) to support biopharma evidence generation. Among many industry trends, experts anticipate that AI and machine learning will increasingly be leveraged to...
Blog
Inflation Reduction Act (IRA): ISPOR Key Takeaways
While attending the ISPOR US 2023 conference in Boston this year, Trinity team members had the opportunity to connect with industry colleagues, present original research, and participate in research panels and discussions regarding key industry trends. One top-of-mind industry topic for...
Blog
ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?
Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez,...
Blog
The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future
Executive Summary Trinity’s Take Introduction As the second highest grossing drug worldwide, with $21.6 billion in global revenue and $17 billion in U.S. revenue in 2021, AbbVie’s Humira is one of the most commercially successful blockbuster therapies of all time. Humira...
Blog
Highlights of the 2022 National Reimbursement Drug List (NRDL) Negotiation Outcome
Executive summary Highlight 1: Increased presence of multinational corporations in newly listed products from the 2022 NRDL negotiations The 2022 NRDL negotiations finished immediately before the week-long Chinese New Year holidays in January 2023, adding 83 novel non-traditional Chinese medicines...
